1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is 24,04€ (+250,95%). The median is 24,04€ (+250,95%).
| Buy |
5 |
| Hold |
7 |
| Sell |
2 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | −1.29m | 212,93% |
| Gross profit | 0.00 | 100,00% |
| Net profit | 10.49m | 262,65% |
| EBITDA | −15.40m | 57,21% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | 31.50m€ |
Number of shares | 4.05m |
52-week high/low | 18,84€ - 4,16€ |
| Dividends | No |
Beta | 0,77 |
P/E ratio | 0,14 |
PEG ratio | 0,00 |
P/B ratio | −1,07 |
P/S ratio | 7,00 |
Company profile
| Name | FibroGen |
| CEO | Thane Wettig |
| Employees | 225 |
Discover assets
Shareholders of FibroGen also invest in the following assets
